Press releases

GSK presents data at AAAAI on efficacy of Nucala® (mepolizumab) in severe asthma patients stratified by eosinophil levels

GSK today presented results at the American Academy of Allergy, Asthma & Immunology annual meeting from a post-hoc study which showed that severe asthma patients with a baseline blood eosinophil count of 150 cells/L or above who received Nucala® (100mg fixed dose subcutaneous injection of mepolizumab) or an investigational dose of mepolizumab had a significant improvement in their exacerbation rates compared to those receiving placebo.

Read more - GSK presents data at AAAAI on efficacy of Nucala® (mepolizumab) in severe asthma patients stratified by eosinophil levels Read more